CLBP , No , the amount of cells per treatment leaves 2D very profitable. Add CHF however 3D becomes almost a necessity, that is before we see the big $$ flowing in. That's because CHF manufacturering by 2D would likely require scaling up big time, a lot of capital would be needed. If 3D was introduced for CHF then large sums of capital would not be required. We have already manufactured multiple lots by 3D for comparison studies used for tthe 3D patents. We obviously have the capacity to manufacturer by 3D.
Can we use 3D.
What say the FDA ?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.035(1.88%) |
Mkt cap ! $2.331B | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.94 | $1.82 | $11.55M | 6.216M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40245 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |